Deoxyribonucleic Acid (DNA) Vaccines Market to Reach Valuation of USD 11.43 Billion by 2028 - Increasing Technological Advancements in the Healthcare Sector is Driving the Market

Vantage Market Research

Feb 02, 2022

In terms of revenue, the Global Deoxyribonucleic Acid (DNA) Vaccines Market is expected to reach USD 11.43 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 7.2% from 2022 to 2028. Rising company initiatives to enhance vaccine-related Research and Development (R&D) activities, growing government support for vaccine development, and the rising focus on immunization are the driving factors for Deoxyribonucleic Acid (DNA) Vaccines Market.

Key Findings:

  • Under the type segment, prophylactic vaccines sub-segment is anticipated to dominate the growth of Deoxyribonucleic Acid (DNA) Vaccines Market at a substantial Compound Annual Growth Rate (CAGR), owing to the availability of prophylactic vaccines for the treatment of animal diseases such as West Nile virus, and Hematopoietic Necrosis virus.
  • Veterinary hospitals sub-segment held a market significant share in 2021. This growth is mainly occurred, owing to a rise in incidences of animal diseases, an increase in hospital admissions of animals for vaccine dose, and the availability of trained veterinarians in the hospitals.
  • North America is the largest regional segment. This is due to its high demand and extraordinary R&D facility provided by the key market players.

Some of key players in Deoxyribonucleic Acid (DNA) Vaccines Market includes - Inovio Biomedical Corp, Merck & Co., Mitsubishi Tanabe, Dendreon Corporation, ASTELLAS PHARMA, Dynavax Technologies, Sanofi, Tekmira Pharmaceuticals GlaxoSmithKline Corp, Protein Sciences Corp.among others.

Diseases can emerge as a result of the deliberate introduction into human, animal, or plant populations due to emerging infectious diseases. These diseases contain anthrax, smallpox, and tularemia. Since the 1970s, about 40 infectious diseases have been discovered, like SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika, and most recently COVID-19, caused by a new coronavirus, SARS-CoV-2. The rising prevalence of these infectious diseases will lead to a continued and growing market for vaccines in the coming years. Also, the emergence of recent diseases will ensure better R&D funding initiatives, a strong pipeline, and new Deoxyribonucleic Acid (DNA) Vaccines prospects for large population segments. DNA Vaccination consists of stimulating the immune system with components of an infectious agent, altered in such a manner that no harm or disease is caused, but providing that when the host is confronted with that infectious agent, the immune system can sufficiently neutralize it before it causes any ill effect.

Deoxyribonucleic Acid (DNA) Vaccines has many potential advantages, including specific targeting, the use of numerous genes to improve immunity, and reduced risk compared with conventional vaccines. Achievements in these fields promise to overcome the translational hurdles and develop strategic opportunities. Emerging markets showcase promising opportunities for the vaccine industry due to their massive patient populations & increasing disposable incomes. This growth potential has drawn major market players to invest in the economies. Various institutions and foundations, such as GAVI, are also launching initiatives to improve the usage of vaccines in evolving countries, by providing vaccines at low costs. This makes such countries major growth hotspots in the vaccines market.

North America is expected to emerge as potential market for Deoxyribonucleic Acid (DNA) Vaccines Market. This is attributed as the emerging countries are growing in demand for low-priced Deoxyribonucleic Acid (DNA) Vaccines products and the presence of well-established veterinary organizational structures. Businesses are investing & focusing on inventing affordable, low-cost vaccines to strengthen the reach of immunization programs in these economies.